trial

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

NCTId NCT07571148
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Active Not Recruiting
Enrollment 6,876 (actual)
Sponsored by Bristol-Myers
Primary completion 2026-03-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
6,876 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2026-01-16
Primary completion
2026-03-25
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Bristol-MyersLead Sponsor

Sites

1 total
Chicago, United States

Facts & assertions

4 sourced
Enrollment
6,876
Phase
NA
Primary Completion Date
2026-03-25
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication